Saxagliptin: 7 agencies, 2009–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “In adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as combination therapy with insulin (with or without metformin), when…”, while AWMSG (Wales) recorded not recommended for “For use in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as monother…”.
Assessment has run over 11.6 years, from 2 Dec 2009 at HAS (France) to 21 Jul 2021 at HAS (France).
SMC (Scotland) changed its position: restricted on 8 Mar 2010, recommended by 10 Nov 2014.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for saxagliptin, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2021; on this evidence the file is dormant.
The programme is broad: 8 distinct indication wordings are recorded for saxagliptin by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess saxagliptin, on 2 Dec 2009; PHARMAC (New Zealand) did not open a file until 21 Feb 2019 — an unusually long tail of 9.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 10 years in total.
4 of the 7 agencies here assessed saxagliptin more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for saxagliptin.
The full ledger for saxagliptin reads 7 recommended, 4 other, 3 not recommended and 3 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 21 Jul 2021 | Re-assessment of SMR and ASMR | SMR insufficient · ASMR V | source |
| PHARMAC (New Zealand) | 21 Feb 2019 | Diabetes - type 2 | PTAC advice: No Formal Recommendation · decision reached | source |
| PBAC (Australia) | 2017 | Type 2 diabetes mellitus (T2DM) | The PBAC deferred making a decision regarding the Authority Required (STREAMLINED) listing… | source |
| G-BA (Germany) | 15 Dec 2016 | Onglyza — benefit assessment §35a | added benefit: not proven | source |
| SMC (Scotland) | 10 Nov 2014 | In adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as combination therapy with insulin (with or without metformin), when… | accepted | source |
15 further decisions for saxagliptin, across 5 agencies, are not shown here. They link to 8 further source documents.
Related molecules
- tirzepatide — divergent outcome (recommended vs not recommended) on a shared indication
- exenatide — divergent outcome (recommended vs not recommended) on a shared indication
- canagliflozin — divergent outcome (recommended vs restricted) on a shared indication
- empagliflozin — same ATC class A10B — Diabetes
- dapagliflozin — same ATC class A10B — Diabetes
- semaglutide — same ATC class A10B — Diabetes
Coverage: 20 decisions for saxagliptin from 7 agencies, 2009 to 2021. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.